{
  "trial_id": "NCT02642458",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Adult breast cancer patients (age \u226518 years)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients with metastatic or locally advanced, unresectable HER2-positive breast cancer",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "proven by clinical measures (i.e. standard imaging) in first line treatment (Locally",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "recurrent disease must not be amenable to resection with curative intent",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients who are eligible for treatment with trastuzumab plus chemotherapy or pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously in a three weekly frequency, according to each center's medical practice.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The first line anti-HER2 treatment must not have started more than 28 days before study entry.",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "No prior chemotherapy or HER2-directed therapy for metastatic or locally advanced disease, prior therapy for early breast cancer (eBC) is allowed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Signed informed consent prior to onset of documentation.",
      "label": "unknown",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has HER2-positive breast cancer and is eligible for treatment with trastuzumab plus chemotherapy. She does not have prior chemotherapy or HER2-directed therapy for metastatic or locally advanced disease.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT02642458",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}